Stock Ratings / Health Care / RGC / forecast

DFTX (52) TRLV (58) CRON (51) TLRY (20) ⌘ Pro Terminal →

Regencell Bioscience Holdings Limited (RGC) 12-Month Stock Forecast & Price Target Cone

$6.71 -2.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.67

Regencell Bioscience Holdings Limited (RGC) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $3.40B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RGC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RGC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Regencell Bioscience Holdings Limited (NASDAQ: RGC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $6.71 (-2.19% 1D, market cap $3.40B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RGC ranks #572 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RGC compare to DFTX and TRLV in the Health Care sector?

▼

Within the Health Care sector (Medicinal Chemicals and Botanical Products), RGC carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DFTX (Definium Therapeutics Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -32.2%, cap $5.10B) and TRLV (Trulieve Cannabis Corp. Subordinate Voting Shares) posts a D+ grade (58/100 RQD, P/E N/A, ROIC 12.8%, cap $2.04B). Among the 5-stock peer group, RGC leads on earnings multiple (N/A) while TRLV leads on capital efficiency (12.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RGC?

▼

Per RGC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001829667), Regencell Bioscience Holdings Limited generated $0 in revenue, -$3.6M in net income, and -$3.3M in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.67 (-0.58%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RGC)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY RGC SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+11/20 pts (29% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$7.13+41% Next Q

Q2 (-2Q)

Grade D$10.05-32.7% Next Q

Q3 (-1Q)

Grade D$6.76-0.7% Next Q

Current

Grade D-$6.71-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RGC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RGC currently carries a cautious 38/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.86) and Max Pain ($7.05) forces dealer call-delta covering toward $72.45.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RGC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RGC Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your RGC Position Size: $10,000

Shares at $6.71: 1490.3 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $4.77

$7,109

$-2,891 (-28.9%)

12M Consensus BaseTarget $6.11

$9,106

$-894 (-8.9%)

12M Bull Case BreakoutTarget $72.45

$107,973

+$97,973 (+979.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$6	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$68	69%	B
JP MorganUS Large-Cap Research	SELL	$5	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RGC)

✓Walkthrough of RGC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RGC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -75.48%🛡️ HOLDING TREND SUPPORT

2026-11-02O $7.27H $7.27L $6.71C $6.71VOL 183.7K

RES: $12.11SUP: $6.65SMA50: $6.86SMA200: $17.03

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RGC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RGC Butterfly Map → + Track RGC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RGC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RGC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RGC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RGC)

Health Care Rank #572 of 1016 ⚔️ DFTX vs RGC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RGC vs. DFTX, TRLV, CRON, TLRY)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Regencell Bioscience Holdings Limited (RGC) ranks #572 by composite RQD confidence (38/100, grade D-) and #195 by equity capitalization ($3.40B). Within this direct 5-issuer industry benchmark cohort, RGC leads on earnings valuation at N/A trailing P/E, while TRLV leads on capital efficiency and profitability with 12.8% ROIC and 60.2% gross margin. TRLV currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with RGC at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RGC ACTIVE Regencell Bioscience Holdings Limited	D-	38/100	—	—	—	-2.19%	$3.40B	Benchmark Subject
DFTX Definium Therapeutics Inc.	D+	52/100	—	—	-32.2%	-4.29%	$5.10B	/dftx-vs-rgc →
TRLV Trulieve Cannabis Corp. Subordinate Voting Shares	D+	58/100	—	60.2%	12.8%	-3.02%	$2.04B	/trlv-vs-rgc →
CRON Cronos Group Inc. Common Share	D	51/100	—	42.8%	-4.5%	-1.79%	$1.24B	/cron-vs-rgc →
TLRY Tilray Brands Inc.	E	20/100	—	28.4%	-3.9%	-4.17%	$390.2M	/tlry-vs-rgc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001829667

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Regencell Bioscience Holdings Limited (RGC) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$3.6M, operating cash flow of -$3.1M, and free cash flow of -$3.3M (+18.5% YoY). On the balance sheet, RGC closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$0	-$3.6M	-$3.1M	-$3.3M	—	—
FY2024 (FY)	2024-06-30	$0	-$4.3M	-$4.0M	-$4.0M	—	—
FY2023 (FY)	2023-06-30	$0	-$5.9M	-$5.0M	-$5.0M	—	—

3. RGC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RGC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does RGC compare to DFTX and TRLV in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for RGC?

Where is RGC trading relative to its 50-day, 200-day, and 52-week technical levels?

RGC last traded at $6.71 (-2.19% on volume of 148,205 shares), positioning the stock -2.19% below its 50-day simple moving average ($6.86) and -60.60% below its 200-day simple moving average ($17.03). Across its 52-week range of $4.51 to $69.00, RGC sits at the 3.4% percentile with a 14-day RSI of 44.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.87 to $7.55).

RGC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is RGC's 12-month stock price target?

Regencell Bioscience Holdings Limited (RGC) carries a 12-month consensus base price target of $6.11 (-8.9% from $6.71), with a bull-case target of $72.45 and a bear-case floor of $4.77.

Is RGC stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates RGC D- (Sell — SELL) with an RQD Confidence score of 38/100.

Direct Sub-Reports: RGC RQD Cockpit RGC 12M Forecast RGC Earnings & Move RGC Dividends & DRIP RGC Insiders & 13F RGC Whale Options RGC Profit Sankey RGC News & Why

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

RGC — Regencell Bioscience Holdings Limited: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:23:26Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, RGC scores 38 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine 11/20 (ROIC 0%; FCF yield -0.1%), Whale 13F Flow 4/20 (institutional accumulation and options positioning), Insider Conviction 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 8/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). For a prospective investor, the weakest pillars are flow-related (13F and insider signals), and the cash engine is scored low because the reported ROIC is 0% and FCF yield is -0.1%, consistent with the negative reported FCF in the SEC financials. The forensic pillar is the strongest of the weak set, with an Altman Z of 2.5 and a Debt/Equity of 0.5, but a Piotroski F of 2/9 signals weak financial strength. Any upside case would have to rest on factors outside the reported cash-generation and flow data, which the source data does not supply.

Business

Regencell Bioscience Holdings Limited is a NASDAQ-listed issuer in the Health Care sector, within the Medicinal Chemicals and Botanical Products industry, per the company profile. The profile does not describe its products, customers, or revenue model. Reported revenue is $0.0M in each of the three SEC financial periods provided. Not available in source data for further business detail.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-3.8M	$-3.6M	N/A	$-3.3M	N/A	N/A
FY 2024	$0.0M	$-4.7M	$-4.3M	N/A	$-4.0M	N/A	N/A
FY 2023	$0.0M	$-6.3M	$-5.9M	N/A	$-5.0M	N/A	N/A

Per the SEC financials, the company reported zero revenue and operating losses across FY 2023–FY 2025, with operating losses narrowing from $-6.3M to $-3.8M. Per the market data, gross, operating, and net margins are each 0%, and ROIC is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Cash and debt balances are not available in source data.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Sector is Health Care and industry is Medicinal Chemicals and Botanical Products. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data.

Open Questions

What products or services generate the company's business, given zero reported revenue across FY 2023–FY 2025?
What are the cash and debt balances, which are marked N/A in the SEC financials?
What drives the 52-week range of $4.51 to $69, and what explains the current price of 6.86?
What is the company's path to positive operating income, given losses in each reported period?
Who are the institutional and insider holders, given that the holders section is NONE?

RGC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Regencell Bioscience Holdings Limited (RGC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RGC Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo • 8d ago

Regencell (RGC) Stock Looks Rich As DOJ Probe Raises Questions

Regencell Bioscience Holdings has seen its share price swing sharply in recent years, which puts fresh focus on whether the current US$7.67 level lines up with what its balance sheet and book value can support. With the

Read Full Source ↗

🔴 RISK WATCH Yahoo • 16d ago

How Investors Are Reacting To Regencell Bioscience Holdings (RGC) Wider Full Year Loss

Regencell Bioscience Holdings reported full year results for the period ended June 30, 2026, with a net loss of US$11.7 million and basic loss per share from continuing operations of US$0.0237, compared with US$3.58 mill

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 18d ago

Which stocks are moving on Thursday?

Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 18d ago

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Regencell Bioscience (NASDAQ:RGC) stock increased by 30.4% to $10.58 during Thursday's regular session. The company's market cap stands at $4.0 billion. SenesTech (NASDAQ:SNES) stock rose 24.93% to

Read Full Source ↗

🟢 CATALYST Benzinga • 19d ago

Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday

U.S. stocks mostly fell, but Bending Spoons surged 40% after Berkshire’s $330M investment. Liquidia and Verastem also posted strong gains.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 20d ago

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers Alaunos Therapeutics (NASDAQ:TCRT) stock moved upwards by 203.8% to $3.19 during Tuesday's regular session. The company's market cap stands at $2.6 million. Picard Medical (AMEX:PMI) stock moved

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RGC Bull vs. Bear Conversation Board — What's Your Call at $6.71?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RGC 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $6.04 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is RGC (D- • RQD 38/100) a Buy at $6.86?

Welcome to the RGC (Regencell Bioscience Holdings Limited) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medicinal Chemicals and Botanical Products. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $5.63 (-17.9%)

Spot @ $6.86

Pump the brakes on RGC — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on RGC, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Regencell Bioscience Holdings Limited expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $7.96 (+16.0%)

Spot @ $6.86

RGC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on RGC, the market is fixating on short-term headline noise in Medicinal Chemicals and Botanical Products and ignoring the balance sheet and cash flow trajectory. At $6.86 (52-wk range $4.51 - $69.00), any beat on forward guidance forces shorts and underweight funds to chase.